AstraZeneca Aktie News

It is not every day that a company makes a habit of turning in positive clinical results at a pace that would make even the most seasoned drug developer blink. Yet AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has managed just that this year, and Shore Capital thinks the torrent of data is enough to justify a fresh uplift to forecasts, even if the real strategic test lies a little further down the road.

London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker AstraZeneca climbed to an all-time high.

Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.

The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of c...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACA...

The global pharmaceutical giant posted some impressive growth numbers in its latest earnings release. It also crushed analyst estimates for profitability.

AstraZeneca PLC ( AZN ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice-Pre...